A Phase IIa Study to Evaluate NBQ72S

Summary

A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.

Timeline

Start

2025-04-22

Primary completion

2026-08-31

Completion

2027-02-28

Drugs

Indications